Vimarsana
Biggest News Aggregation in the World

Page 11 - Priya Singhal News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Priya Singhal. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Priya Singhal Today - Breaking & Trending Today

Alzheimer's drug adoption in US slowed by doctors' skepticism - Vimarsana News

Alzheimer's drug adoption in US slowed by doctors' skepticism

CHICAGO (Reuters) -Nine months into the U.S. launch of the first drug proven to slow the advance of Alzheimer's, Eisai and Biogen's Leqembi is facing an unexpected hurdle to widespread use: an entrenched belief among some doctors that treating the memory-robbing disease is futile. Alzheimer's experts had anticipated bottlenecks due to Leqembi's requirements, which include additional diagnostic tests, twice-monthly infusions and regular brain scans to guard against potentially lethal side effects. And those issues have played a role in slow adoption since the drug was appr...

Source: yahoo.com
Illinois Municipal Retirement Fund Has $12.71 Million Stock Position in Biogen Inc. (NASDAQ:BIIB) - Vimarsana News

Illinois Municipal Retirement Fund Has $12.71 Million Stock Position in Biogen Inc. (NASDAQ:BIIB)

Illinois Municipal Retirement Fund lowered its stake in shares of Biogen Inc. (NASDAQ:BIIB – Free Report) by 28.2% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 49,117 shares of the biotechnology company’s stock after selling 19,274 shares during the period. Illinois Municipal […]

Source: wkrb13.com
Alzheimer's drug embrace slows down as US doctors' reluctance grows - Vimarsana News

Alzheimer's drug embrace slows down as US doctors' reluctance grows

The adoption of the FDA-approved Alzheimer's drug, Leqimbi, has slowed down in the U.S. as more experts grow hesitant about the drugs cost, risks and efficacy.

Biogen (NASDAQ:BIIB) Price Target Lowered to $213.00 at Wedbush - Vimarsana News

Biogen (NASDAQ:BIIB) Price Target Lowered to $213.00 at Wedbush

Biogen (NASDAQ:BIIB – Free Report) had its price objective reduced by Wedbush from $245.00 to $213.00 in a research report released on Wednesday morning, Benzinga reports. They currently have a neutral rating on the biotechnology company’s stock. Wedbush also issued estimates for Biogen’s Q1 2024 earnings at $3.25 EPS, Q3 2024 earnings at $4.13 EPS, […]

OVERSEA CHINESE BANKING Corp Ltd Grows Stake in Biogen Inc. (NASDAQ:BIIB) - Vimarsana News

OVERSEA CHINESE BANKING Corp Ltd Grows Stake in Biogen Inc. (NASDAQ:BIIB)

OVERSEA CHINESE BANKING Corp Ltd raised its stake in Biogen Inc. (NASDAQ:BIIB – Free Report) by 6.8% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 11,770 shares of the biotechnology company’s stock after purchasing an additional 750 shares during the quarter. […]